They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition ...

Miracure Biotechnology Ltd. has divulged Toll-like receptor 7 (TLR7) and/or TLR8 agonists reported to be useful for the treatment of cancer, infections, respiratory disorders and immunological ...

This represents the first time a mutation in the TLR7 gene has been directly linked to the onset of lupus, offering new ...

Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed Toll-like receptor 7 (TLR7) and/or TLR8 and/or TLR9 antagonists reported to be useful for the treatment of ...

Merck’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development of the drug is set to continue. Announced in the company’s Q4 earnings call, ...

The lead Eikon drug, EIK1001, is a small molecule designed to hit toll-like receptors 7 and 8 (TLR7/8). Activating these receptors is intended to spark an immune response that fights cancer.

Its lead candidate, MBS8, consists of a small-molecule agonist of Toll-like receptor 7 (TLR7) in-licensed from the University of California San Diego, USA, and formulated by MonTa in collaboration ...

Two new studies led by researchers at Hospital for Special Surgery (HSS) have uncovered key biological mechanisms driving systemic sclerosis (SSc), or ...

Patients with systemic lupus erythematosus (SLE) often require pulsed intravenous glucocorticoid therapy if oral glucocorticoids fail to control their disease. Why are doses of steroids that ...